QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Intellia Therapeutics, Inc. (NTLA)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
1

Do Nothing: fundamentalScore is 2 (below the required floor of 3), so the fundamental gate blocks any bullish entry regardless of the chart; separately, no entry type qualifies — a pullback/oversold limit is countertrend (price 10.55 < SMA50 11.98 with MACD -0.22 < 0, and below a declining SMA200 12.98 with SMA50 < SMA200 and no momentum reclaim), and no breakout stop qualifies (price is below every short-term average with MACD expanding negative, so a stop above the nearest settled swing high 12.15 would be a chase into overhead supply).

Analysis as of 2026-11-12· more than 2 trading days ago

Company overview

Intellia Therapeutics, Inc. is a biotechnology company focused on developing therapeutic treatments using genome editing. It has several in vivo and ex vivo programs targeting conditions like transthyretin amyloidosis and hereditary angioedema, leveraging CRISPR/Cas9 technology. The company collaborates with partners like Novartis and Regeneron to advance its pipeline.

Fundamental

weak
Fundamental2
Weak fundamentals

Intellia's fundamentals are weak, with no product revenue, significant net losses, and a high dilution risk.

Pre-revenue CRISPR gene-editing company where strong liquidity ($614.8M cash and securities at 30-Sep-2026, runway guided into 2028, no going concern, no funded debt until a $75M secured draw in September 2026) is offset by a $330.4M nine-month net loss, revenue down 33% year to date, an 11.1% senior secured facility pledging all assets including IP, and roughly 21% share-count growth in nine months with $368.5M of ATM capacity remaining. Operating cash burn is improving while the income statement is not; conventional multiples and both DCF models are non-meaningful for a company with no product revenue, and the equity is effectively a binary bet on the 10-Mar-2027 lonvo-z regulatory decision, with nex-z safety, patent litigation and an open dilution spigot as the main downside amplifiers.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is mixed with both positive clinical data and negative financial results impacting the outlook.

A genuinely mixed setup: the tape is working through a Q3 2026 print it sold (EPS -$0.91 vs -$0.82; revenue $7.2M vs $9.7M FactSet; two aggregator items scored -0.4 and Yahoo ran 'Q3 Loss Wider Than Expected, Stock Down') against three announced bullish legs — same-day positive lonvo-z ACAAI 2026 data, completed MAGNITUDE-2 Phase 3 enrollment, and a regulator-confirmed lonvo-z PDUFA on 2027-03-10. Media sentiment shows a determinate but modest cooling (baseline polarity ~ +0.23 on n=3 to scoring ~ -0.05 on n=9) rather than a negative flip; retail is indeterminate after a Reddit 403 block; no severe red flag fired. Because the actionable window holds both bullish and bearish catalysts, the moderate conflicting-catalysts flag fires and a moderate red-flag cap applies.

Technical

very weak
Technical1
Downtrend

The stock is in a downtrend, trading below key moving averages with no bullish confirmation.

Bearish/broken structure with no bullish confirmation anywhere in the stack: price 10.55 sits below the SMA20 (11.75), SMA50 (11.98) and SMA200 (12.98) and below every short-lag average (EMA9 11.45, EMA21 11.72, WMA9 11.35, WMA21 11.70, DEMA14 11.31, TEMA14 11.11) as well as the day's VWAP 10.7675; MACD is negative (-0.22) below its signal (-0.10) with the histogram expanding negative (-0.12 vs +0.05 on 2026-11-04); RSI14 is 40.92 and falling; Williams %R is -97.41; ADX14 is 10.76 (weak, direction-agnostic strength reading). The stock closed 0.06 above the session low after a -7.5% session, the latest in a run of lower highs from 13.16 (10-30) to 11.06 (11-12). Fundamentals independently block the trade (fundamentalScore 2 < 3), but the chart itself earns a 1.

You’re looking at 2026-11-12 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.